Special Issue "Editorial Board Members’ Collection Series: Targeted Delivery of Anticancer Agents Engaging Cell Specific Mechanisms"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: 30 June 2023 | Viewed by 839

Special Issue Editors

1. Biological Faculty, Moscow State University, Moscow 119234, Russia
2. Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilov St., Moscow 119334, Russia
Interests: subcellular drug delivery; drug delivery carriers; delivery of auger-electron emitters; cell-penetrating antibody mimetics
Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
Interests: target discovery and validation; drug discovery and development; assay design and optimization; chemogenomics

Special Issue Information

Dear Colleagues,

The aim of anticancer therapy is to kill tumor cells with minimal harm to non-tumor cells. Cell determinants located on the surface of tumor cells can be used for specific recognition of these cells in cases where these determinants differ qualitatively or quantitatively from those of non-tumor cells. Transport machinery of tumor cells is also often exploited for the purposes of internalization of anticancer agents and/or for their delivery to specific subcellular structures and macromolecules. This Special Issue is devoted to the newest achievements in the field of engagement of cell mechanisms for tumor-specific delivery of anticancer agents and aims to consider targeted delivery of toxic agents with the help of antibodies/antibody mimetics or ligands to specific tumor cell receptors, non-toxic agents metabolized in tumor cells into toxic agents, as well as targeted delivery utilizing cell transport systems, cell metabolism, DNA repair systems, and defective vasculature of tumors.

We look forward to receiving your contributions.

Prof. Dr. Alexander S. Sobolev
Dr. Katerina Gurova
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticancer agents
  • antibodies
  • antibody mimetics
  • cell determinants
  • cellular transport
  • gene delivery
  • subcellular drug delivery
  • targeted drug delivery
  • targeted delivery of radionuclides
  • internalization
  • molecular recognition
  • receptor-mediated endocytosis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells
Pharmaceutics 2023, 15(3), 987; https://doi.org/10.3390/pharmaceutics15030987 - 19 Mar 2023
Viewed by 721
Abstract
A large number of proteins are successfully used to treat various diseases. These include natural polypeptide hormones, their synthetic analogues, antibodies, antibody mimetics, enzymes, and other drugs based on them. Many of them are demanded in clinical settings and commercially successful, mainly for [...] Read more.
A large number of proteins are successfully used to treat various diseases. These include natural polypeptide hormones, their synthetic analogues, antibodies, antibody mimetics, enzymes, and other drugs based on them. Many of them are demanded in clinical settings and commercially successful, mainly for cancer treatment. The targets for most of the aforementioned drugs are located at the cell surface. Meanwhile, the vast majority of therapeutic targets, which are usually regulatory macromolecules, are located inside the cell. Traditional low molecular weight drugs freely penetrate all cells, causing side effects in non-target cells. In addition, it is often difficult to elaborate a small molecule that can specifically affect protein interactions. Modern technologies make it possible to obtain proteins capable of interacting with almost any target. However, proteins, like other macromolecules, cannot, as a rule, freely penetrate into the desired cellular compartment. Recent studies allow us to design multifunctional proteins that solve these problems. This review considers the scope of application of such artificial constructs for the targeted delivery of both protein-based and traditional low molecular weight drugs, the obstacles met on the way of their transport to the specified intracellular compartment of the target cells after their systemic bloodstream administration, and the means to overcome those difficulties. Full article
Show Figures

Figure 1

Back to TopTop